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Abstract 
Objective: The threonine/serine kinase glycogen synthase kinase 3 (GSK-3) targets multiple substrates in T-cells, 
regulating the expression of Tbet and PD-1 on T-cells. However, it has been unclear whether GSK-3 can affect the 
motility of T-cells and their interactions with antigen presenting cells.
Results: Here, we show that GSK-3 controls T-cell motility and interactions with other cells. Inhibition of GSK-3, using 
structurally distinct inhibitors, reduced T-cell motility in terms of distance and displacement. While SB415286 reduced 
the number of cell-cell contacts, the dwell times of cells that established contacts with other cells did not differ for 
T-cells treated with SB415286. Further, the increase in cytolytic T-cell (CTL) function in killing tumor targets was not 
affected by the inhibition of motility. This data shows that the inhibition of GSK-3 has differential effects on T-cell 
motility and CTL function where the negative effects on cell–cell interactions is overridden by the increased cytolytic 
potential of CTLs.
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Introduction
T-cells are activated via a tyrosine kinase phosphoryla-
tion cascade that is initiated when the T-cell receptor 
(TCR) recognises foreign antigens, or tumor neoantigens, 
as presented by major histocompatibility (MHC) anti-
gens. The cascade is initiated by the immune cell src 
kinase  p56lck which we showed binds to the cytoplas-
mic tails of co-receptors CD4 and CD8 [1–3]. Co-rec-
ognition of MHC-antigen by the TCR, and CD4 or CD8, 
brings  p56lck into proximity of the TCR for the phospho-
rylation of immunoreceptor tyrosine-based activation 
motifs (ITAMs) in the cytoplasmic tails of the CD3 and 
the ζ-subunits of the TCR-CD3 complex [2]. Phospho-
ITAMs then bind to a second tyrosine kinase, zeta-chain 
associated protein kinase 70 (ZAP-70) which is further 
activated by  p56lck [4].  p56lck and ZAP-70 phosphorylate 
downstream substrates that include adaptors or scaffolds 
which form multimeric complexes that integrate signals 
for T-cell effector functions. Examples of key adaptors 
include the linker for activation of T-cells (LAT) [5] and 
Src homology (SH)2 domain-containing leukocyte pro-
tein-76 (SLP-76) [6] which regulate intracellular calcium, 
or adhesion and degranulation-promoting  adapter  pro-
tein (ADAP) and Src kinase-associated phosphoprotein 1 
(SKAP1) which activate LFA-1 adhesion [7–9].
By contrast, glycogen synthase kinase 3 (GSK-3) 
is a serine/threonine kinase that is active in resting 
T-cells and is inactivated upon T-cell activation [10, 
11]. Isoforms of GSK-3 α and β differ in their N- and 
C-terminal sequences. TCR ligation induces GSK-3 inac-
tivating phosphorylation [12–14], while the expression of 
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active GSK-3β (GSK-3βA9) inhibits the proliferation of 
T-cells [12]. GSK-3 phosphorylation also regulates cellu-
lar metabolism [15] and microtubule-associated protein 
2C (MAP2C) regulation of microtubule re-modelling [16, 
17]. Protein kinase B (PKB/AKT) and its downstream 
target GSK-3 in T-cells appear to operate independently 
of guanine nucleotide exchange factor VAV-1 [13]. Fur-
ther, in  CD4+ T-cells, GSK-3 promotes the exit of nuclear 
factor of activated T-cells (NFAT) [18, 19]. Clinical tri-
als using GSK-3 inhibitors have been undertaken in the 
treatment of type II diabetes and various neurological 
disorders [11, 20, 21]. Recently, we reported that the inac-
tivation of GSK-3α/β specifically down-regulates PD-1 
expression for enhanced cytolytic T-cell (CTL) function 
and the  clearance of infection by Murid herpes virus-4 
and lymphocytic choriomeningitis virus (LCMV) clone 
(Cl) 13 [22]. Further, we showed that GSK-3 inactivation 
is as effective as anti-PD-1 blockade in the regression of 
melanoma and lymphoma tumors [23, 24].
In this study, we assessed whether GSK-3 inhibition 
affects T-cell movement and interactions with other cells. 
Structurally distinct inhibitors of GSK-3 reduced T-cell 
motility as measured by velocity, distance and  displace-
ment. The consequence of this was to reduce the number 
of cell contacts with other cells. However, a  concurrent 
increase in CTL function in killing tumor targets was not 
substantially affected by the inhibitory effect of GSK-3 




Primary mouse T-cells (OT-1, C57BL/6, 6–8  weeks 
old) were isolated from spleens and cultured in  vitro 
in RPMI 1640 medium supplemented with 10% FCS, 
50  μM β-mercaptoethanol, 2  mM  l-glutamine, 100 U/
ml penicillin and streptomycin (GIBCO). Spleen cells 
were treated with a hypotonic buffer containing 0.15 M 
NH4CL, 10 mM KHCO3 and 0.1 mM EDTA, pH 7.2 to 
eliminate red blood cells before suspension in supple-
mented RPMI 1640 medium. A T-cell enriched popula-
tion was purified by use of T-cell purification columns 
(R&D Systems, Minneapolis, MN). All mouse experi-
ments were approved by the Home Office UK (PPL No. 
70/7544).  EL4 lymphoma cells were cultured in RPMI 
medium that was supplemented as above.
Cytotoxicity assays
OVA specific  CD8+ CTLs were generated by incubating 
isolated splenocytes from OT-1 Tg mice with SIINFEKL 
peptide of OVA  (OVA257–264) at 10 ng/mL for 5–7 days. 
For in  vitro cytotoxic assays, T-cells were plated in 
96-well plates at the start of culture with activating EL4 
cells (EL4-OVA) pulsed with  OVA257–264 peptide. EL4 
cells were incubated with 10  nM  OVA257–264 peptide 
(Bachem) for 1 h at 37 °C prior to co-culture at a ratio of 
1:5 of EL4 and T-cell. CTLs were generated in the pres-
ence or absence of GSK-3 inhibitor for 7 days prior to co-
culture. GSK-3 inhibitors SB415286, SB216763 (Abcam 
plc) and L803-mts (Tocris) were reconstituted in DMSO 
to give a stock solution of 25 mM and diluted to a con-
centration of 10µM in  vitro. Cytotoxicity was assayed 
using a Cytotox 96 nonradioactive kit (Promega) follow-
ing the instructions provided.
Live cell imaging
T-cells were labelled using Carboxyfluorescein succin-
imidyl ester (CFSE, Biolegend) and EL4-OVA target cells 
labelled with  CellTrackerTM Red CMTPX Dye (Thermo 
Fisher Scientific). Imaging was performed using co-
cultures on Poly-l-lysine-treated chambered glass cul-
ture slides (Lab-tek). Cells were imaged at the interface 
using a Zeiss LSM 510 confocal microscope using exci-
tation wavelengths of 492 nm for CFSE and 577 nm for 
 CellTrackerTM Red and a × 63 oil immersion objective. 
Images were collected at 10 second intervals. All images 
were processed by Volocity software (Improvision).
Statistical analysis
Statistical significance was tested using one-way analy-
sis of variance (ANOVA) between groups and a series 
of   T-tests using GraphPad Prism version 3.02 (Graph-
Pad Software, San Diego, California, U.S.A.), p < 0.05 was 
considered as significant.
Results
Inhibition of GSK‑3 slows T‑cell motility
In order to assess the role of GSK-3 in T-cell motility, 
T-cells (OT-1 Tg) were initially imaged over a period of 
5  min in the presence or absence of GSK-3 inhibitors 
(Fig. 1a), SB415286 (left panel), SB216763 (middle panel) 
and L803-mts (right panel). In the absence of SB415286, 
T-cells moved with a mean velocity of 4µm/min with a 
wide range of motilities from 7µm/min to 2µm/min. 
The presence of SB415286 slowed cells with an average 
velocity of 1um/min (i.e. 75% reduction). Similar pro-
files were observed when other parameters were used to 
assess movement (Fig.  1b, c). The displacement showed 
a reduction from 46µm to 2.5µm (Fig. 1b) and the length 
also was reduced from 104µm to 30µm (Fig. 1c). Spider 
graphs also illustrated the reduced distance travelled over 
time (Fig. 1d). Similar results were obtained using other 
structurally distinct inhibitors of GSK-3, all of which have 
been previously shown to decrease PD-1 expression and 
potentiate OT-I killing of targets [22, 23]. These included 
ATP-competitive inhibitors, L803-mts (Fig.  1,  Right 
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panels) and SB216763 (Fig.  1, middle panels). The pep-
tide L803-mts (11 residues) is a cell-permeable phospho-
rylated peptide that is derived from the GSK-3 substrate 
heat shock factor-1 (HSF-1) and is structurally unre-
lated to SB415286 and SB216763 [25]. SB216763 has a 
preference for the GSK-3alpha isoform, while L803-mts 
preferentially inhibits GSK-3beta. These data therefore 
collectively showed that GSK-3 kinase activity is needed 
for the optimal migration of T-cells (Fig. 2). 
The result of reduced motility could lead to an increase 
or decrease in contacts with other cell types. For exam-
ple, disruption of adaptors needed for integrin binding 
reduces contacts with antigen presenting cells [26, 27]. 
Interestingly, the presence of SB415286 reduced the total 
number of contacts of OT-1 Tg T-cells with antigen-
presenting cells by approx.  50% (Fig.  2a), with a mean 
of 73 contacts in the untreated cells verses 40 contacts 
in the inhibitor-treated cells (SD =  4.3 and 2.9, respec-
tively); however, surprisingly,  GSK-3 inhibition had no 
significant effect on the duration of cell  contact which 
occurred (Fig. 2b). This reduction of contacts can be seen 
further when looking at individual target cells (Fig.  2c). 
Fig.  2c  (left panel) shows 20 individual target cells 
(EL  4-OVA) and the number of contacts made. In the 
absence of SB415286 the mean number of contacts was 
3.25 (SD ± 0.27). This was reduced to a mean of 1.75 con-
tacts (SD ± 0.22) in the presence of SB415286. The right 
panel of Fig.  2c depicts the mean number of contacts 
from 3 independent experiments giving an overall mean 
of 3.8 ± 0.15 in the absence of SB415286 and 1.7 ± 0.1 in 
the presence of SB415286. These data show for the first 
time that GSK-3 activity is needed for optimal interac-
tions of T-cells with other cells.
Fig. 1 GSK-3 inhibition decreases T-cell motility. Cells treated with GSK-3 inhibitors (Left panel: SB415286, Middle panel: SB216763, right panel: 
L803-mts) for 7 days show reduced motility in the presence of target cells (EL4-OVA). Tracking of 30 individual cells showed differences in a velocity, 
b displacement and c length of track travelled. Spider plots (d) show the traced tracks of all cells in area imaged. Data shown representative of three 
independent experiments. **** P value < 0.0001. Mean shown ± standard deviation
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To address whether the effects of GSK-3 inactivation 
on reducing T-cell motility and numbers of contracts was 
reflected in target killing, we next cultured CTLs with 
SB415286 for various times and assessed levels of killing 
(Fig. 3). We previously reported that long term exposure 
of primary T-cells to SB415286 increased the potency of 
killing by resultant CTLs [22–24]. Indeed, the culturing 
of T-cells for 7 days in the presence of SB415286 poten-
tiated the killing of EL4-OVA targets.  The increase in 
killing efficiency seen was 3- to 5-fold for effector:target 
ratios of 2:1 through to 25:1. An effector:target ratio of 
2:1 with inhibitor showed the same efficiency of kill-
ing as seen at a ratio of 25:1 for non-inhibitor treated 
cells (Fig.  3a). By contrast, we next assessed whether 
the presence of  GSK-3  inhibitors had an effect  follow-
ing the actual generation of armed CTLs, the generated 
CTLs were exposed to SB415286 for 24 h (Fig. 3b) or 4 h 
(Fig. 3c) and were assessed for killing. The brief exposure 
of CTLs to SB415286 had no detectable effect after a 4 h 
incubation, the same period that we showed could affect 
T-cell motility. Fig. 3d shows an example of the killing of 
a tumor target with the bubbling of membranes charac-
teristic of cell death. Therefore, surprisingly, over the time 
frame where SB416286 could affect motility, no detecta-
ble effect on the killing of tumor targets was evident. The 
CTLs were, therefore, sufficiently potent in killing targets 
so that the GSK-3 effects on T-cell motility and numbers 
of contacts did not appreciably affect the overall killing of 
tumor targets in the in vitro assays of killing.
Fig. 2 SB415286 decreases T-cell contacts with other cells. Inhibition of GSK-3 reduces the number of cell-to-cell contacts required to induce target 
killing. Quantification of contact times a total number of contacts for each condition, (Ova alone Mean = 72.67 ± 4.3, Plus SB415286 Mean = 40.00 
± 2.89). b GSK3 inhibition does not alter the dwell times of T-cells. % of contacts with different durations of contact is shown. Data shown is pooled 
from (N) = 3 independent experiments. n.s no significant difference. c Left panel, number of contacts by each individual target cell tracked (n = 20 
Target cells (EL4-OVA)). Right panel, Mean number of contacts by individual target cells from (N) = 3 independent experiments (Ova alone Mean 
= 3.8 ± 0.15, Plus SB415286 Mean = 1.7 ± 0.10). * P < 0.05; ** P < 0.005; *** P < 0.0005
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Discussion
Overall, the rationale of our study was to assess whether 
GSK-3 inhibition effects are seen at the level of T-cell 
velocity and interactions with other cells. Our study 
shows that GSK-3 plays a clear role in regulating the 
movement of T-cells and interactions with other cells. 
Indeed, the inhibition of GSK-3 reduced the velocity of 
T-cells as measured in vitro on plates coated with ICAM1 
for adhesion. The net result of this was to reduce T-cell 
velocity and also reduce the distance, otherwise needed 
to  travel to interact with other cells. By contrast,  the 
actual duration of the cell-cell  interactions or the dwell 
Fig. 3 GSK-3 inactivation requires long-term incubation with T-cells to enhance CTLs killing of tumors. GSK inhibitor increases cytolytic killing of 
CTLs when present during over the cell culture period needed to induce differentiation. CTLS were generated by incubating splenocytes from OT-1 
Tg mice with OVA-peptide for 7 days. SB415286 was added to cultures on a day 0 or b day 6. On day 7 T-cells were washed and a 4 h cytolytic assay 
performed using EL-4 cells pulsed or non-pulsed with Ova-peptide as target cells.  c depicts T-cells only treated with SB415286 following the wash 
step and prior to the 4 h CTL assay (In panels a and b any residual SB415296 was washed away). Error bars based on triplicate values in individual 
experiments, data shown representative of 3 independent experiments. * P < 0.05; ** P < 0.005; *** P < 0.0005. d Figure shows examples of T-cells 
interacting and killing tumor targets (EL4-OVA cells labelled in red). The CTL then goes on to lyse the cell as can be seen from the characteristic 
bubbling of the cell cytoplasm and the clear vacuole. Data shown representative of three independent experiments
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times was not affected by GSK-3  inhibition. Movement 
is needed for T-cells to stochastically encounter other 
cell types or to respond to chemo-attractants such as 
chemokines.
The fact that GSK-3 inhibition does not have an effect 
within minutes of exposure but rather requires longer 
periods of incubation following activation suggests that 
its effect on motility may be less important for the effects 
of GSK-3 inhibition  on CTL klling may be less impor-
tant than the more long term effects of inhibition  on 
T-cell activation or differentiation. Naive murine T-cells 
become effector T-cells followed by the generation of 
central memory T-cells [28]. We previously showed that 
GSK-3 regulates this event leading to more potent CTLs 
[22–24, 29, 30]. The potential disadvantage of reduced 
motility and interactions with other cells appears to 
be  overridden by the positive intracellular effects on 
CTL differentiation [22–24, 29].
Further, it is important to note that different inhibitors 
of GSK-3 had the same effect on T-cell motility. L803-
mts is structurally unrelated to SB415286 and SB2167763 
[25]. Further, SB216763 has a preference for the GSK-
3alpha isoform, while L803-mts preferentially inhibits the 
GSK-3beta isoforms. Despite different structures and iso-
form specificities, the exposure of cells to all drugs over-
time resulted in population of cells with reduced motility 
after long-term exposure.
The underlying mechanism of GSK-3 on T-cell motil-
ity  is not clear. As mentioned, the effects require long-
term incubation with T-cells, and are, therefore, most 
likely related to effects on the activation or differentia-
tion of T-cells. However, effects on more proximal events 
are also possible since GSK-3 can phosphorylate micro-
tubule-associated protein 2C (MAP2C) which prevents 
microtubule remodelling [16, 17]. It is also possible that 
GSK-3 interfaces with adaptor proteins such as SKAP1 
which regulate T-cell motility [31]. The N-terminal region 
of SKAP1 binds to RapL such that a RapL mutation 
(L224A) abrogates SKAP1 binding and arrests T-cells 
even in the absence of antigen [17]. Lastly, it is possible 
that GSK-3 may influence cell motility and chemotaxis by 
regulating Phosphoinositide 3-kinase (PI 3 K) membrane 
localization as has been  observed  in Dictyostelium [32] 
or due to effects on phosphatidylinositol-3,4,5-triphos-
phate (PIP3) metabolism, the  target of rapamycin com-
plex (TORC)2 signaling, and remodeling of F-actin [33, 
34]. Teo et al. have reported that gsk3−  cells respond to 
stimuli with a reduced increase of PIP3 and no TORC2 
activation [34], decreased adenylyl cyclase, while oth-
ers have obtained different results [33]. Future work will 
be needed to assess the full range of effects of GSK-3 
on aspects of T-cell function linked to motility and 
migration.
Limitations
Work restricted to non-lymphoid cells.
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